HIV among injection drug users in large US metropolitan areas, 1998

Journal of Urban Health

Volumn 82, Issue 3, 2005, Pages 434-445

  Friedman, Samuel R ^a,b   Lieb, Spencer ^c   Tempalski, Barbara ^a   Cooper, Hannah ^a,d   Keem, Marie ^a   Friedman, Risa ^a   Flom, Peter L ^a  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c FLORIDA DEPARTMENT OF HEALTH   (United States)

^d National Development and Research Institutes Inc ^*  (United States)

Author keywords

Epidemic modeling; HIV prevalence estimates; Injection drug users; Local epidemics; Structural analysis

Indexed keywords

ARTICLE; CALCULATION; CORRELATION ANALYSIS; EPIDEMIC; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCOME; INJECTION; MAJOR CLINICAL STUDY; PATIENT COUNSELING; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REGRESSION ANALYSIS; SOCIAL ASPECT; SUBSTANCE ABUSE; SYRINGE; THEORETICAL STUDY; UNITED STATES; VALIDATION PROCESS;

EPIDEMIOLOGIC RESEARCH DESIGN; HIV INFECTIONS; HUMANS; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES; URBAN POPULATION;

EID: 23944520161     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jti088     Document Type: Article

References (41)

1. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642-654.
2. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programs for prevention of HIV infection. Lancet. 1997;21:1797-1800.
3. MacDonald M, Law M, Kaldor J, Hales J, Dore G. Effectiveness of needle and syringe programmes for preventing HIV transmission. Int J Drug Policy. 2000;14:351-352.
4. Friedman SR, Perlis TE, Lynch J, Des Jarlais DC. Economic inequality, poverty, and laws against syringe access as predictors of metropolitan area rates of drug injection and HIV infection. In: NIDA, eds. 2000 Global Research Network Meeting on HIV Prevention in Drug-Using Populations. Third Annual Meeting Report. Durban, South Africa, July 5-7, 2000. Washington, DC: US Department of Health and Human Services; 2001:147-149.
5. Office of Management and Budget. Standards for defining metropolitan and micropolitan statistical areas. Federal Register. 2000;65:8228-82238.
6. U.S. Bureau of the Census. State and Metropolitan Area Data Book, 1997-1998. Washington, DC: U.S. Bureau of the Census; 1998.
7. Lieb S, Friedman SR, Zeni MB, et al. An HIV prevalence-based model for estimating urban risk-populations of injection drug users and men who have sex with men. J Urban Health. 2004;81:401-415.
8. Friedman SR, Tempalski B, Cooper H, et al. Estimating numbers of IDUs in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for IDUs. J Urban Health. 2004;1:377-400.
9. Centers for Disease Control and Prevention. Adult HIV/AIDS Confidential Case Report Form CDC 50. 42A, Rev. 01/.2003;1:2003.
10. Centers for Disease Control and Prevention. Characteristics of persons living with AIDS and HIV, 2001. HIV/AIDS Surveillance Supplemental Report [serial online]. 2003;9:2. Available at: http://www.cdc.gov/hiv/stats/ hasrsuppVol9No2.htm. Accessed July 12, 2003.
11. Fleming PL, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV prevalence in the United States, 2000. Paper presented at 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Wash.
12. Perlis T, Des Jarlais DC. Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health. 2001;91:791-793.
13. Friedman SR, Tempalski B, Cooper H, Keem M, Friedman R, Flom PL. Structural factors to guide structural intervention: predictors of IDU population size, HIV prevalence among IDUs, and prevention program coverage for IDUs. Paper presented at: International Conference on AIDS; July 11-16, 2004; Bangkok, Thailand.
14. Des Jarlais DC, Perlis TE, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991-96. Am J Public Health. 1998;88:1801-1806.
15. Des Jarlais DC, Marmor M, Friedmann P, et al. HIV incidence among injection drug users in New York City, 1992-97: evidence for a declining epidemic. Am J Public Health. 2000;90:352-359.
16. Samuel MC, Doherty PM, Bulterys M, Jension SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect. 2001;127:475-484.
17. Rothenberg R, Baldwin J, Trotter R, Muth S. The risk environment for HIV transmission: results from the Atlanta and Flagstaff network studies. J Urban Health. 2001;78:419-431.
18. Centers for Disease Control and Prevention. National HIV Prevalence Surveys 1997 Summary. Atlanta, GA. Centers for Disease Control and Prevention; 1998.
19. Monterroso ER, Hamburger ME, Vlahov D, et al. Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS). J Acquir Immune Defic Syndr. 2000;25:63-70.
20. Shah NG, Celentano DD, Vlahov D, et al. Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. AIDS. 2000;14:2035-2043.
21. Strathdee SA, Safaeian M, Doherty M, Garfein RS, et al. Correlates of HIV infection among young new initiates to injection drug use in Baltimore, MD. 1994-2000. Paper presented at: XIV. International AIDS Conference; July 7-12, 2002; Barcelona, Spain.
22. Valente TW, Foreman RK, Junge B, Vlahov D. Needle-Exchange participation, effectiveness and policy: syringe relay, gender, and the paradox of public health. J Urban Health. 2001;78:340-349.
23. Ouellet LJ, Thorpe LE, Huo D, et al. Prevalence and incidence of HIV among out-of-treatment injecting drug users, Chicago 1994-96. J Acquir Immune Defic Syndr Hum Retrovirol. 2000;25:443-450.
24. Kwiatkowski CF, Corsi KF, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Soc Study Addict Alcohol Other Drugs. 2002;97:1-6.
25. California Department of Health Services. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California; December, 2001; Sacramento, Calif.
26. Michigan Department of Public Health. 2002 Profile of HIV/AIDS in Region 5; 2003; Michigan Department of Public Health, Lansing, Mich.
27. Buchanan RJ, Smith SR. Drug-assistance programs funded by Title II of the Ryan White CARE Act: a survey of the states. AIDS Public Policy J. 1996;11:185-203.
28. Weeks MR, Clair S, Singer M, et al. High risk drug use sites, meaning and practice: implications for AIDS prevention. J Drug Issues. 2001;31:781-808.
29. Lopez-Zetina J, Kerndt P, Ford W, Woerhle T, Weber M. Prevalence of HIV and hepatitis B and self-reported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994-96. Addiction. 2001;96:589-595.
30. Lopez-Zetina J, Norton D, Friis R, Rios-Ellis B, Kerndt P. Gender differences in participation in drug treatment among street-recruited injection drug users (IDUs) in Los Angeles County. Paper presented at XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain.
31. Murrill CS, Prevots DR, Miller MS, Linley LA, Royalty JE, Gwinn M. Incidence of HIV among injection drug users entering drug treatment programs in four US cities. J Urban Health. 2001;78:152-161.
32. Chitwood DD, Sanchez J, Comerford M, Page JB, McBride DC, Kitner KR. First injection and current risk factors for HIV among new and long-term injection drug users. AIDS Care. 2000;12:313-320.
33. Longshore D, Annon J, Anglin MD. HIV prevalence among injection drug users in three northern California communities. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:200.
34. Clarke JG, Stein MD, Hanna L, Sobota M, Rich JD. Active and former injection drug users report of HIV risk behaviors during periods of incarceration. Subst Abuse. 2001;22:209-216.
35. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001;1:211-215.
36. Zule WA, Desmond DP, Neft JA. Syringe type and drug injector risk for HIV infection: a case study in Texas. Soc Sci Med. 2002;55:1103-1113.
37. Buchsbaum L, Stafford K, Velasco A. Risk Behavior Study: Injection Drug Users in San Diego County. San Diego, CA: County of San Diego Health and Human Services Agency, Office of AIDS Coordination; 1998.
38. McFarland W, Kellogg TA, Louie B, Murrill C, Katz MH. Low estimates of HIV seroconversions among clients of a drug treatment clinic in San Francisco, 1995-98. J Acquir Immune Defic Syndr. 2000;23:426-429.
39. Urban Health Study, AIDS Research Institute, University of California San Francisco, Urban Health Study Research Findings. Available at: http://www.ucsf.edu/uhs/program.html. Accessed February 4, 2005.
40. Gibson DR, Brand R, Anderson K, Kahn JG, Perales D, Guydish J. Two- to sixfold decreased odds of HIV risk behavior associated with use of syringe exchange. J Acquir Immune Defic Syndr. 2002;31:237-242.
41. Thiede H, Romero M, Bordelon K, Hagan H, Murrill CS. Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users. J Urban Health. 2001;78:264-278.